Kyowa Hakko Kirin Co., Limited

Nichias Corporation

Asahi Glass Company, Limited

Dicerna Pharmaceuticals, Inc.

Kyowa Kirin Co., Ltd.

Nichias Co., Ltd.

Takeshi Kuboyama

Tomoyuki Naoi

Tomohiro Era

Michihiko Suzuki

Arata Yanagisawa

Keisuke Yamamoto

Tomohiro Tamura

Masayuki Saito

Keiji Uehara

Masahiro Matsubara

Kimihisa Ueno

Tomoya Shimizu

Shintaro Hosoe

Naoya Kuzawa

Kaori Yagi

Hitoshi Arai

Haruhiko Manabe

Tatsuo Takagi

Kohichi Kimura

Hitoshi Yamada

Tetsuya Miwa

Kozo Yao

Seiji Aratake

Kyoichiro Iida

Toshihiko Ishii

Kentaro Hatanaka

Akihiko Watanabe

Takumi Arisawa

Kazuki Morimoto

Yukihito Tsukumo

Kazuki Hemmi

Nobumasa Otsubo

Kinro Hashimoto

Hitoshi Ogura

Kojiro Otani

Naoko Hiura

Hideyuki Shishitani

Junichi Enokizono

Mayumi Saki

Nobuhiro Yagi

Akihiro Tokunaga

Akinori Hamaguchi

Kentarou Hatanaka

Munehiko Fukase

Masanori Ono

Hidenori Takada

Jun Saito

The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.

Nucleic acid-containing lipid nanoparticles

The present invention addresses the problem of reducing the hardness of a molded article obtained by cross-linking a cross-linking elastomer. The problem addressed by the present invention is solved by cross-linking a cross-linking elastomer composition including at least a cross-linking elastomer and a fluorine oligomer (a) not including hydrogen.

Crosslinkable elastomer composition, molded article, seal member, plasma treatment apparatus and semiconductor manufacturing apparatus including said seal member, and agent for decreasing hardness of molded article, method for producing molded article

Provided are a cationic lipid which facilitates the introduction of a nucleic acid into, for example, a cell or the like; a composition containing the cationic lipid and a nucleic acid; a method for introducing a nucleic acid into a cell by using a composition containing the cationic lipid and the nucleic acid; and the like. The cationic lipid is, for example, a cationic lipid represented by formula (A): formula (A): (wherein Ris alkenyl or the like, Ris alkenyl or the like, Rand Rare each alkyl, or are combined together to form alkylene, or Rand Rare combined together to form alkylene, Ris a hydrogen atom or the like, or is combined together with Rto form alkylene, Xis alkylene, and Xis a single bond or alkylene).

Cationic lipid

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) 

The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and a cationic lipid represented by the following formula (I): wherein  

RNAi pharmaceutical composition for suppressing expression of KRAS gene

The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: Rand Rare, the same or different, alkenyl, etc, and 

Lipid nano particles comprising cationic lipid for drug delivery system

The invention provides a method of activating PPAR &#x3b3; and a method of treating or preventing a disease associated with PPAR &#x3b3; by administering a tricyclic compound having a PPAR &#x3b3; agonist activity, which is represented by the formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A represents aryl or the like, B and C are the same or different and each represents an aromatic carbocycle or the like, R-Rare the same or different and each represents hydrogen or the like, V represents a single bond or the like, Rand Rare the same or different and each represents hydrogen or the like, or a pharmaceutically acceptable salt thereof or the like: 

Tricyclic compound

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: Rand Rare, the same or different, alkenyl, etc, and Xand Xare hydrogen atoms, or are combined together to form a single bond or alkylene, and Xis absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and Lis a single bond, etc, Ris alkyl, etc, Land Lare &#x2014;O&#x2014;, &#x2014;CO&#x2014;O&#x2014; or &#x2014;O&#x2014;CO&#x2014;), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like. 

The present invention provides a perfluoroelastomer composition comprising: a perfluoroelastomer having a nitrogen-containing curing site; and a catalyst mixture comprising: a tertiary amine; and an organic dicarboxylic acid represented by general formula (1) or (2) in an amount of 0.4 to 2 mol per mol of the tertiary amine:HOOC&#x2014;COOH&#x2003;&#x2003;(1)HOOC-A-COOH&#x2003;&#x2003;(2)wherein A in formula (2) is an alkyl group having 1 to 10 carbon atoms or a phenyl group, which may be partially or fully fluorinated. Also disclosed is a perfluoroelastomer molded article obtained from the composition.

Perfluoroelastomer composition and molded article hereof

The present invention provides a preventive and/or therapeutic agent for neutrophilic inflammatory diseases which comprises, as an active ingredient, a bicyclic heterocyclic compound represented by formula (I): [wherein Rrepresents a hydrogen atom, substituted or unsubstituted alkyl, or the like, A-A-A-Arepresents N&#x2550;CR&#x2014;CR&#x2550;CR(wherein R, R, and Rare the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like), Q represents substituted or unsubstituted phenylene, and the like, and T represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aroyl, and the like].

Preventive and/or therapeutic agent for neutrophilic inflammatory diseases

Provided is a tricyclic compound having a PPAR &#x3b3; agonist activity, which is represented by the general formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A represents aryl or the like, B and C are the same or different and each represents an aromatic carbocycle or the like, R-Rare the same or different and each represents hydrogen or the like, V represents a single bond or the like, Rand Rare the same or different and each represents hydrogen or the like, or a pharmaceutically acceptable salt thereof or the like: 

The present invention provides a PPAR &#x3b3; agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) (wherein Rrepresents lower alkyl optionally having substituent(s) or the like, Rand Rare the same or different and each represents lower alkyl optionally having substituent(s) or the like, Rand Rare the same or different and each represents a hydrogen atom or the like, Q-Q-Qrepresents CH&#x2550;CH&#x2014;CH&#x2550;CH or the like, Y represents a single bond or the like, Z-Zrepresents C&#x2550;CR(wherein Rrepresents a hydrogen atom or the like), or the like, and A represents &#x2014;COOH or the like), or a pharmaceutically acceptable salt thereof and the like.

Tricyclic compounds

Moldings of fluoro rubbers produced by crosslinking a tetrafluoroethylene/propylene copolymer or a tetrafluoroethylene/propylene/vinylidene fluoride copolymer, which have metal contents of 1.5% by mass or below in terms of metal elements and are suitable for use applications necessitating clean environment, for example, manufacturing or carrier equipment for semiconductors, manufacturing equipment, carriers, or storage containers for food, or medical supplies.

Moldings of fluororubbers and process for their production

In an oil application roller having an oil retaining member made of a hollow cylindrical porous formed body provided with an oil application layer on the outer periphery and that supplies a fixing roll with lubricant oil retained in the oil retaining member, the porous formed body is made of an inorganic material having micro-diameter voids and pores inside, at least a part of the micro-diameter voids communicates with a surface of the porous formed body and the pores, and at least a part of the pores communicates with a surface of the porous formed body through the micro-diameter voids. Also, if permeability resistance is 100 to 6,000 Pa.s/m , no oil leak occurs during transportation and storage, the amount of the lubricant oil supplied to the fixing roll can be controlled and a uniform amount of lubricant oil can be supplied despite its compact and simple structure, the utilization rate of the lubricant oil can be enhanced. Further, if a pressure buffer device is provided between the hollow portion and the atmosphere, ill effects from oil leak and thermal expansion can be prevented.

Oil application roller

Growing community of inventors

Tokyo, Japan

Takeshi Kuboyama